BR9913939A - Composto, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, e, método para o tratamento da dor, febre ou inflamação - Google Patents

Composto, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, e, método para o tratamento da dor, febre ou inflamação

Info

Publication number
BR9913939A
BR9913939A BR9913939-1A BR9913939A BR9913939A BR 9913939 A BR9913939 A BR 9913939A BR 9913939 A BR9913939 A BR 9913939A BR 9913939 A BR9913939 A BR 9913939A
Authority
BR
Brazil
Prior art keywords
group
alkyl
compound
pharmaceutical composition
hydroxycarbonyl
Prior art date
Application number
BR9913939-1A
Other languages
English (en)
Inventor
Maria Isabel Crespo Crespo
Juan Miguel Jimenez Mayorga
Carles Puig Duran
Lidia Soca Pueyo
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES9802011A external-priority patent/ES2154561B1/es
Priority claimed from ES009900619A external-priority patent/ES2168895A1/es
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of BR9913939A publication Critical patent/BR9913939A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTO, PROCESSO PARA A PREPARAçãO DO MESMO, USO DO MESMO, E, COMPOSIçãO FARMACêUTICA" Derivados de 2-fenilpiran-4-ona da fórmula (I) onde R¹ representa um grupo alquila ou NR^ 4^R^ 5^, onde R^ 4^ e R^ 5^ cada um deles independentemente representa um átomo de hidrogênio ou um grupo alquila; R² representa um grupo alquila, cicloalquila C~ 3~-C~ 7~, piridila, tienila, naftila, tetrahidronaftila ou indanila, ou um grupo fenila o qual pode ser insubstituido ou substituído por um ou mais átomos de halogênio ou grupos alquila, trifluormetila, hidroxi, alcoxi, metiltio, amino, mono -ou dialquilamino, hidroxialquila ou hidroxicarbonila; R³ representa um grupo metila, hidroximetila, alcoximetila, cicloalcoximetila C~ 3~-C~ 7~, benziloximetila, hidroxicarbonila, nitrila, trifluormetila ou difluormetila ou um grupo CH~ 2~-R^ 6^ onde R representa um grupo alquila; e X representa uma ligação só, um átomo de oxigênio, um átomo de enxofre ou um grupo metileno; ou sais farmaceuticamente aceitáveis dos mesmos, processos para a sua produção e intermediários sintéticos utilizados nos referidos processos, composições farmacêuticas contendo os mesmos e seu uso em tratamentos médicos.
BR9913939-1A 1998-09-25 1999-09-16 Composto, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, e, método para o tratamento da dor, febre ou inflamação BR9913939A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES9802011A ES2154561B1 (es) 1998-09-25 1998-09-25 Derivados de 2-fenilpiran-4-ona.
ES009900619A ES2168895A1 (es) 1999-03-26 1999-03-26 Derivados de 2-fenilpiran-4-ona.
PCT/EP1999/006873 WO2000018753A1 (en) 1998-09-25 1999-09-16 2-phenylpyran-4-one derivatives

Publications (1)

Publication Number Publication Date
BR9913939A true BR9913939A (pt) 2001-06-12

Family

ID=26155180

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913939-1A BR9913939A (pt) 1998-09-25 1999-09-16 Composto, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, e, método para o tratamento da dor, febre ou inflamação

Country Status (34)

Country Link
US (1) US6518303B2 (pt)
EP (1) EP1115716B1 (pt)
JP (1) JP4717211B2 (pt)
KR (1) KR100806684B1 (pt)
CN (1) CN1202104C (pt)
AR (1) AR021826A1 (pt)
AT (1) ATE230405T1 (pt)
AU (1) AU765653B2 (pt)
BG (1) BG65308B1 (pt)
BR (1) BR9913939A (pt)
CA (1) CA2345069C (pt)
CO (1) CO5140127A1 (pt)
CZ (1) CZ300357B6 (pt)
DE (1) DE69904738T2 (pt)
DK (1) DK1115716T3 (pt)
EE (1) EE04812B1 (pt)
EG (1) EG23802A (pt)
ES (1) ES2190252T3 (pt)
HK (1) HK1034961A1 (pt)
HU (1) HUP0104620A3 (pt)
ID (1) ID28624A (pt)
IL (1) IL142087A0 (pt)
MX (1) MXPA01003069A (pt)
MY (1) MY121793A (pt)
NO (1) NO327987B1 (pt)
NZ (1) NZ510625A (pt)
PE (1) PE20001067A1 (pt)
PL (1) PL346895A1 (pt)
RU (1) RU2232158C2 (pt)
SI (1) SI1115716T1 (pt)
SK (1) SK286471B6 (pt)
TR (1) TR200100852T2 (pt)
TW (1) TW587079B (pt)
WO (1) WO2000018753A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011333A1 (es) 2000-03-16 2002-01-16 Almirall Prodesfarma Ag Derivados de 2-fenilpiran-4-ona como inhibidores de ciclooxigenasa 2
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
ES2214130B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 2-3'-bipiridinas.
ES2213485B1 (es) * 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US304728A (en) * 1884-09-09 Maubice hellwig
CH524614A (de) * 1969-12-31 1972-06-30 Ciba Geigy Ag Verfahren zur Herstellung von neuen Imidazolderivaten
US3901908A (en) * 1970-12-28 1975-08-26 Ciba Geigy Corp 2-alkyl- and 2-cycloalkyl-4,5-bis-phenyl-imidazoles
US4304728A (en) * 1979-04-05 1981-12-08 Lilly Industries Limited 6-Substituted pyranone compounds and their use as pharmaceuticals
IL59748A (en) 1979-04-05 1983-11-30 Lilly Industries Ltd 5-substituted pyranone derivatives,their production and pharmaceutical compositions containing them
JPS5834446B2 (ja) * 1979-05-22 1983-07-27 三省製薬株式会社 消炎剤
JPH0768234B2 (ja) * 1989-12-14 1995-07-26 久光製薬株式会社 コウジ酸エステル誘導体
EP0489877B1 (en) * 1990-06-29 1995-09-20 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones
JPH04173391A (ja) * 1990-11-07 1992-06-22 Sanyo Chem Ind Ltd 感熱記録用増感剤および感熱記録用材料
DE4103904C2 (de) * 1991-02-08 1995-06-14 Analyticon Ges Fuer Chemische Neue Arzneimittel aus Gamma-Pyronen, Gamma-Pyridonen sowie Gamma-Thiopyronen
US6048850A (en) 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
WO1995014014A2 (en) * 1993-11-19 1995-05-26 Parke, Davis & Company Pyrone derivatives as protease inhibitors and antiviral agents
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
EA199700209A1 (ru) 1995-04-04 1998-04-30 Глаксо Груп Лимитед ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА
CA2224517A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
BR9813998A (pt) * 1997-11-19 2000-09-26 Kowa Co Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos

Also Published As

Publication number Publication date
CN1202104C (zh) 2005-05-18
EP1115716B1 (en) 2003-01-02
AR021826A1 (es) 2002-08-07
EE200100173A (et) 2002-08-15
EG23802A (en) 2007-08-22
ES2190252T3 (es) 2003-07-16
NZ510625A (en) 2002-12-20
MY121793A (en) 2006-02-28
TR200100852T2 (tr) 2001-10-22
WO2000018753A1 (en) 2000-04-06
US6518303B2 (en) 2003-02-11
NO20011512L (no) 2001-05-25
PL346895A1 (en) 2002-03-11
BG105373A (en) 2001-11-30
ATE230405T1 (de) 2003-01-15
CZ20011058A3 (cs) 2001-08-15
ID28624A (id) 2001-06-21
US20020045644A1 (en) 2002-04-18
CA2345069A1 (en) 2000-04-06
CO5140127A1 (es) 2002-03-22
PE20001067A1 (es) 2000-10-23
CA2345069C (en) 2009-03-10
AU6084799A (en) 2000-04-17
EP1115716A1 (en) 2001-07-18
DE69904738T2 (de) 2003-04-30
IL142087A0 (en) 2002-03-10
HUP0104620A3 (en) 2003-01-28
SK286471B6 (sk) 2008-11-06
MXPA01003069A (es) 2002-07-02
HK1034961A1 (en) 2001-11-09
CN1324352A (zh) 2001-11-28
KR100806684B1 (ko) 2008-02-26
SI1115716T1 (en) 2003-06-30
SK3702001A3 (en) 2001-12-03
KR20010075369A (ko) 2001-08-09
DE69904738D1 (de) 2003-02-06
BG65308B1 (bg) 2008-01-31
NO20011512D0 (no) 2001-03-23
HUP0104620A2 (hu) 2002-04-29
CZ300357B6 (cs) 2009-04-29
EE04812B1 (et) 2007-04-16
NO327987B1 (no) 2009-11-02
JP4717211B2 (ja) 2011-07-06
RU2232158C2 (ru) 2004-07-10
DK1115716T3 (da) 2003-02-24
JP2002525364A (ja) 2002-08-13
AU765653B2 (en) 2003-09-25
TW587079B (en) 2004-05-11

Similar Documents

Publication Publication Date Title
BR0210638A (pt) Piridinas substituìdas por herbicidas, processos para a sua preparação e sua aplicação como herbicidas e reguladores do crescimento de plantas
BR0214989A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças, e, processo para a preparação de um composto
BR9913939A (pt) Composto, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, e, método para o tratamento da dor, febre ou inflamação
BR9714787A (pt) Compostos de 4- fenilpiperidina e processo para sua preparação
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
BR0113120A (pt) Composto ou sal, composição farmacêutica, método para alterar a atividade transdutora de sinal de receptores gabaa, método para o tratamento de ansiedade, depressão, um distúrbio do sono, ou demência de alzheimer, método para demonstrar a presença de receptores de gabaa em amostras de célula ou tecido, embalagem, e, uso de um composto ou sal
BR0113039A (pt) Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
BR9915011A (pt) Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto
BR9810829A (pt) Composto, processo para preparar o mesmo, composição, uso de um composto ou um sal farmaceuticamente aceitável do mesmo ou uma composição, e, processo de tratamento de uma condição
DK60887A (da) Piperazinderivater og deres anvendelse til fremstilling af laegemidler med antiarrythmisk virkning
BRPI0015203B8 (pt) derivado de quinazolina, composição farmacêutica, e, uso de um composto
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
BR9911182A (pt) Composto, uso do mesmo, processo para o tratamento de um mamìfero, incluindo homem, de condições suscetìveis de melhora por um agonista de beta-adrenorreceptor atìpico, composição farmacêutica, e, processo para a preparação de um composto.
BR0111596A (pt) Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças
BRPI0409110A (pt) derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer
BR0008763A (pt) Derivados de piridopiranoazepinas, a preparação dos mesmos e a respectiva aplicação em terapêutica
BR0003848A (pt) Compostos de piridina, processo para sua preparação e composições farmacêuticas que os contêm
BR0113697A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou sal, embalagem e métodos para, para alterar a atividade transdutora de sinal dos receptores de gabaa, para tratar ansiedade, depressão, um distúrbio do sono, ou demência de alzheimer, para demonstrar a presença dos receptores de gabaa em células ou amostras de tecido e para preparar um composto
BR0315995A (pt) Composto, uso de um composto composição farmacêutica, métodos para a terapia da dor, de distúrbios gastrointestinais, e da ansiedade em um animal de sangue quente, e, processo para preparar um composto
BR0315998A (pt) Composto, uso de mesmo, composição farmacêutica, métodos para a terapia da dor e de distúrbios gastrointestinais funcionais em um animal de sangue quente, e, processo para preparar um composto
PT91435A (pt) Processo para a preparacao de aril-alquil-aminas e -amidas possuindo propriedades anticonvulsivas e neuroprotectoras e de composicoes farmaceuticas que as contem
DK122191A (da) Benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
PT1042326E (pt) Novos derivados da acronicina processo para a sua preparacao e as composicoes farmaceuticas que os contem
BR0317289A (pt) Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ALMIRALL PRODESFARMA AG (CH)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1849 DE 13/06/2006 POR TER SIDO APRESENTADA PAPELETA DE ESCLARECIMENTO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 309/38, C07D 309/40, C07D 405/04, C07D 409/04, A61K 31/35, A61P 29/00, C07C 317/24, C07C 311/29

Ipc: C07D 309/38 (2008.04), C07D 309/40 (2008.04), C07D

B25D Requested change of name of applicant approved

Owner name: ALMIRALL AG (CH)

Free format text: ALTERADO DE: ALMIRALL PRODESFARMA AG

B25A Requested transfer of rights approved

Owner name: LABORATORIOS ALMIRALL, S.A. (ES)

Free format text: TRANSFERIDO DE: ALMIRALL AG

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AOS ARTIGOS 8O E 13 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 309/38, C07D 309/40, C07D 405/04, C07D 409/04, A61K 31/35, C07C 317/24, C07C 311/29

Ipc: C07D 309/38 (2009.01), C07D 309/40 (2009.01), C07D

B12B Appeal against refusal [chapter 12.2 patent gazette]